About Ikaria
Ikaria is a company based in Hampton (United States) founded in 2005 was acquired by Mallinckrodt Pharmaceuticals in March 2015. Ikaria has raised $434.92 million across 6 funding rounds from investors including Mallinckrodt Pharmaceuticals, Arch Venture Partners and 5AM Ventures. The company has 429 employees as of December 31, 2014. Ikaria operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
- Headquarter Hampton, United States
- Employees 429 as on 31 Dec, 2014
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$434.92 M (USD)
in 6 rounds
-
Latest Funding Round
$850 M (USD), Debt – Conventional
Jul 01, 2013
-
Investors
Mallinckrodt Pharmaceuticals
& 6 more
-
Employee Count
429
as on Dec 31, 2014
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Ikaria
Ikaria has successfully raised a total of $434.92M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $850 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ikaria
Ikaria has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, Arch Venture Partners and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked |
Investor details for Ikaria
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ikaria
Investment portfolio details for Ikaria
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ikaria
Detailed financials for Ikaria
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ikaria Comparisons
Peer comparison for Ikaria
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ikaria
Ikaria operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Pulmatrix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of respiratory diseases
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for various diseases.
|
Detailed competitors of Ikaria
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ikaria
Complete news archive for Ikaria
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ikaria
Ikaria was founded in 2005.
Ikaria is headquartered in Hampton, United States. It is registered at Hampton, Virginia, United States.
Ikaria is a funded company, having raised a total of $434.92M across 6 funding rounds to date.
As of Dec 31, 2014, the latest employee count at Ikaria is 429.
Ikaria was founded in 2005 and is headquartered in Hampton, United States. Focus is placed on developing therapies for respiratory-related cardiopulmonary disorders within the biotechnology sector. INOtherapy is provided, incorporating INOMAX (nitric oxide) for inhalation, which has received FDA approval for hypoxic respiratory failure. Late-stage trials are ongoing for bronchopulmonary dysplasia and acute respiratory distress syndrome. Pipeline efforts address hepatorenal syndrome, heart failure, tissue ischemia, and vascular leakage.
Ikaria's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.
Ikaria has 7 investors. Key investors include Mallinckrodt Pharmaceuticals, Arch Venture Partners, 5AM Ventures, Venrock, and Washington Research Foundation.